Neuronostics Limited - Period Ending 2023-12-31

Neuronostics Limited - Period Ending 2023-12-31


Neuronostics Limited 11123728 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is that of the development of biomarkers from human brain data that can support neurologists and clinical scientists in the diagnosis and management of neurological conditions. Digita Accounts Production Advanced 6.30.9574.0 true true 11123728 2023-01-01 2023-12-31 11123728 2023-12-31 11123728 bus:OrdinaryShareClass1 2023-12-31 11123728 bus:OrdinaryShareClass2 2023-12-31 11123728 core:RetainedEarningsAccumulatedLosses 2023-12-31 11123728 core:ShareCapital 2023-12-31 11123728 core:SharePremium 2023-12-31 11123728 core:CurrentFinancialInstruments 2023-12-31 11123728 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 11123728 core:Non-currentFinancialInstruments core:AfterOneYear 2023-12-31 11123728 core:PatentsTrademarksLicencesConcessionsSimilar 2023-12-31 11123728 core:WithinOneYear 2023-12-31 11123728 core:FurnitureFittingsToolsEquipment 2023-12-31 11123728 bus:SmallEntities 2023-01-01 2023-12-31 11123728 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 11123728 bus:FullAccounts 2023-01-01 2023-12-31 11123728 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 11123728 bus:RegisteredOffice 2023-01-01 2023-12-31 11123728 bus:Director1 2023-01-01 2023-12-31 11123728 bus:Director2 2023-01-01 2023-12-31 11123728 bus:Director3 2023-01-01 2023-12-31 11123728 bus:Director4 2023-01-01 2023-12-31 11123728 bus:Director5 2023-01-01 2023-12-31 11123728 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 11123728 bus:OrdinaryShareClass2 2023-01-01 2023-12-31 11123728 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 11123728 core:PatentsTrademarksLicencesConcessionsSimilar 2023-01-01 2023-12-31 11123728 core:ComputerEquipment 2023-01-01 2023-12-31 11123728 core:FurnitureFittingsToolsEquipment 2023-01-01 2023-12-31 11123728 countries:EnglandWales 2023-01-01 2023-12-31 11123728 core:PatentsTrademarksLicencesConcessionsSimilar 2022-12-31 11123728 core:FurnitureFittingsToolsEquipment 2022-12-31 11123728 2022-01-01 2022-12-31 11123728 2022-12-31 11123728 bus:OrdinaryShareClass1 2022-12-31 11123728 bus:OrdinaryShareClass2 2022-12-31 11123728 core:RetainedEarningsAccumulatedLosses 2022-12-31 11123728 core:ShareCapital 2022-12-31 11123728 core:SharePremium 2022-12-31 11123728 core:CurrentFinancialInstruments 2022-12-31 11123728 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 11123728 core:Non-currentFinancialInstruments core:AfterOneYear 2022-12-31 11123728 core:PatentsTrademarksLicencesConcessionsSimilar 2022-12-31 11123728 core:WithinOneYear 2022-12-31 11123728 core:FurnitureFittingsToolsEquipment 2022-12-31 11123728 bus:OrdinaryShareClass1 2022-01-01 2022-12-31 11123728 bus:OrdinaryShareClass2 2022-01-01 2022-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 11123728

Neuronostics Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2023

Pages for filing with Registrar

 

Neuronostics Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 10

 

Neuronostics Limited

Company Information

Directors

Mr D Buller

Mr R Haycock

Ms A P Hyland

Prof J Terry

Dr W Woldman

Registered office

Engine Shed
Station Approach
Bristol
BS1 6QH

Registered number

11123728

Accountant

Corrigan Accountants Limited
1st Floor
25 King Street
Bristol
BS1 4PB

 

Neuronostics Limited

(Registration number: 11123728)
Balance Sheet as at 31 December 2023

Note

2023
£

2022
£

Fixed assets

 

Intangible assets

4

45,157

30,735

Tangible assets

5

6,589

3,095

 

51,746

33,830

Current assets

 

Debtors

6

55,252

98,990

Cash at bank and in hand

 

733,758

96,796

 

789,010

195,786

Creditors: Amounts falling due within one year

7

(72,591)

(138,918)

Net current assets

 

716,419

56,868

Total assets less current liabilities

 

768,165

90,698

Creditors: Amounts falling due after more than one year

7

(13,166)

(20,608)

Net assets

 

754,999

70,090

Capital and reserves

 

Called up share capital

8

168

124

Share premium reserve

1,827,270

477,879

Profit and loss account

(1,072,439)

(407,913)

Total equity

 

754,999

70,090

 

Neuronostics Limited

(Registration number: 11123728)
Balance Sheet as at 31 December 2023

For the financial year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised for issue by the Board on 22 February 2024 and signed on its behalf by:
 

.........................................

Prof J Terry
Director

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

1

Statutory information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Engine Shed
Station Approach
Bristol
BS1 6QH

2

Accounting policies

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in pounds sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Going concern

The accounts have been prepared on a going concern basis which assumes that the company has sufficient funds to continue to trade for the foreseeable future. The directors have indicated their willingness to continue to support the company and accordingly the accounts have been prepared on the basis that the company is a going concern.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

Government grants

Government grants are recognised, using the accrual model, at the fair value of the asset received or receivable when there is reasonable assurance that the company will comply with conditions attaching to them and the grants will be received.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible fixed assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Computer equipment

Straight line over 3 years

Intangible fixed assets

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Patents and licences

Straight line over 10 years

Research and development costs

Research and development costs are written off to profit or loss in the year incurred.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

Trade creditors

Trade creditors are recognised at the transaction price.

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense.

The cost of any unused holiday entitlement is recognised in the period in which the employees' services are received.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 11 (2022 - 11).

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

4

Intangible fixed assets

Patents and licences
£

Cost

At 1 January 2023

39,130

Additions

18,332

At 31 December 2023

57,462

Amortisation

At 1 January 2023

8,395

Amortisation charge

3,910

At 31 December 2023

12,305

Carrying amount

At 31 December 2023

45,157

At 31 December 2022

30,735

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

5

Tangible fixed assets

Computer equipment
£

Cost

At 1 January 2023

14,442

Additions

7,419

At 31 December 2023

21,861

Depreciation

At 1 January 2023

11,347

Charge for the year

3,925

At 31 December 2023

15,272

Carrying amount

At 31 December 2023

6,589

At 31 December 2022

3,095

6

Debtors: amounts falling due within one year

2023
£

2022
£

Prepayments

3,111

3,076

Other debtors

3,026

19,774

Corporation tax

49,115

76,140

55,252

98,990

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

7

Creditors

2023
£

2022
£

Amounts falling due within one year

Trade creditors

3,597

112,552

Taxation and social security

28,203

12,472

Other creditors

2,408

-

Accruals

31,182

6,934

Bank borrowings

7,201

6,960

72,591

138,918

2023
£

2022
£

Due after one year

Bank borrowings

13,166

20,608

8

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary of £0.0001 (2022 - £0.01) each

1,519,590

151.96

12,375

123.75

A Ordinary of £0.0001 (2022 - £0) each

161,812

16.18

-

-

 

1,681,402

168.14

12,375

123.75

At the start of the year all the shares were subdivided increasing the number of shares from 12,375 to 1,237,500.

During the year, 282,090 Ordinary shares and 161,812 A Ordinary shares with an aggregate nominal value of £44.39 were issued for an aggregate consideration of £1,349,435.

 

Neuronostics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

9

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2023
£

2022
£

10,800

13,440